Autolus Therapeutics plc (AUTL)

Market Cap	372.08M
Revenue (ttm)	2.72M
Net Income (ttm)	-163.55M
Shares Out	173.06M
EPS (ttm)	-1.85
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,260,963
Open	2.02
Previous Close	1.99
Day's Range	1.96 - 2.15
52-Week Range	1.60 - 5.04
Beta	1.56
Analysts	Buy
Price Target	8.64 (+301.86%)
Earnings Date	Mar 9, 2023

About AUTL

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 22, 2018
• Employees: 324
• Stock Exchange: NASDAQ
• Ticker Symbol: AUTL

Financial Performance

In 2021, AUTL's revenue was $2.33 million, an increase of 35.86% compared to the previous year's $1.72 million. Losses were -$142.10 million, 0.00% more than in 2020.

Analyst Forecast

According to 17 analysts, the average rating for AUTL stock is "Buy." The 12-month stock price forecast is $8.64, which is an increase of 301.86% from the latest price.

Price Target

$8.64

(301.86% upside)

Analyst Consensus: Buy